2002
DOI: 10.1016/s0010-8545(02)00050-4
|View full text |Cite
|
Sign up to set email alerts
|

Design of iron chelators with therapeutic application

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
255
0
1

Year Published

2005
2005
2019
2019

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 268 publications
(260 citation statements)
references
References 100 publications
4
255
0
1
Order By: Relevance
“…[65][66][67][68][69][70][71][72][73] Most uses of chelating materials are based on the stable complexation of metal ions by multi-dentate or cyclic ligands which are entropically favored by the ionic chelate over the main solvent molecules, whether organic solvents or water. The concept of scavenging Mn cations and HF from the electrolyte solution of an LMO-graphite cell was first proposed by Tarascon and coworkers in 1999 13 .…”
Section: A6316mentioning
confidence: 99%
“…[65][66][67][68][69][70][71][72][73] Most uses of chelating materials are based on the stable complexation of metal ions by multi-dentate or cyclic ligands which are entropically favored by the ionic chelate over the main solvent molecules, whether organic solvents or water. The concept of scavenging Mn cations and HF from the electrolyte solution of an LMO-graphite cell was first proposed by Tarascon and coworkers in 1999 13 .…”
Section: A6316mentioning
confidence: 99%
“…Many literature articles gave evidence to the developing significance of the discipline [1][2][3][4][5][6][7][8][9][10][11]. Several chelating agents used clinically may create in most pharmacopoeia [12], while other new one still being sought [13]. Due to Cu(II) free ion toxicity, many medical problems can be improved, such as using of chelating agents in treatment of Wilson's disease [14].…”
Section: Introductionmentioning
confidence: 99%
“…28,30 Pyridinones have been proposed as oral therapeutic chelators for Fe III and Al III removal, 31,32 and the compound 1,2-dimethyl-3-hydroxy-4-pyridinone (Hdhp -Scheme 1), commercially known as Deferiprone®, is used in the treatment of β-thalassaemia. [31][32][33] The complexation of V IV O 2+ and V V O 2 + with dhp was studied in aqueous solution [34][35][36][37][38] and exhibited quite interesting insulin like properties. 12,13,39,40 Aiming at developing ligands with similar structural and binding ability characteristics of pyridinone and pyrone heterocycles, with improved aqueous solubility, we developed a distinct heterocyclic ligand system of the pyrimidinone type: 2-methyl-3H-5-hydroxy-6-carboxy-4-pyrimidinone ethyl ester, or mhcpe -Scheme 1 -containing two N atoms in the ring.…”
Section: Introductionmentioning
confidence: 99%